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INTRODUCTION
Cost-effectiveness is an important
dimension of appropriate prescribing.1–4
General practices are under increasing
pressure to control prescribing costs while
continuing to improve health outcomes;5
put simply, this means prescribing drugs
when there is good evidence to indicate that
they will improve health and avoiding them
if evidence for significant benefit is lacking.
Evidence from a number of studies in
England and the US has shown that
prescribing can be ‘cost ineffective’,6–10
thereby indicating that some GPs find it
difficult to know when to avoid prescribing.
There are currently no generally
applicable methods for measuring the
cost-effectiveness of prescribing and
monitoring it against national benchmarks.
Cost data are available, but low
pharmaceutical cost alone is not a clear
indicator of cost-effective prescribing, as it
may be due to the under-treatment of high-
benefit patients which can result in poor
outcomes and high future care costs.
Information on outcomes is harder to find,
but process measures — which have been
linked to improved outcomes — are
routinely available. Indicators in the Quality
and Outcomes Framework (QOF), a UK
national pay-for-performance programme,
are a good example;11 they are also useful
because the pharmaceutical costs
associated with prescribing to patients
included in the QOF can be estimated
reasonably accurately. There are 26 clinical
indicators in the QOF (Appendix 1), all of
which include a prescribing intervention
that is clinically effective; 22 have evidence
for mortality reduction (Appendix 2) and
many have evidence for cost-
effectiveness.12,13
A large-scale national study was
conducted to determine whether
prescribing is cost-effective. Routine data,
which are available in the NHS at general-
practice level, were used to develop a
method for providing a simple and partial
indication of the cost-effectiveness of
prescribing by general practices. It was
hypothesised that if all GPs prescribe in a
cost-effective manner with regard to QOF
indicators and other areas of prescribing, a
higher achievement of QOF quality
indicators will be associated with a higher
related pharmaceutical spend.
METHOD
Data on quality of care from the QOF were
combined with data on related
pharmaceutical costs from the Prescribing
Analysis and Cost (PACT) database. The
practice-level relationship between
quality-indicator performance and
associated pharmaceutical costs was
analysed and adjusted for practice-level
variables that are known to be associated
with need, across eight different
prescribing areas.8
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Abstract
Background
Both pharmaceutical costs and quality-
indicator performance vary substantially
between general practices, but little is known
about the relationship between prescribing
costs and quality.
Aim
Tomeasure the association between
prescribing quality and pharmaceutical costs
among English general practices.
Designandsetting
Cross-sectional observational study using data
from the Quality and Outcomes Framework and
the Prescribing Analysis and Cost database
from all 8409 general practices in England in
2005–2006.
Method
Correlation between practice achievement of 26
prescribing quality indicators in eight
prescribing areas and related pharmaceutical
costs was examined.
Results
There was no significant association between
the overall achievement of quality indicators and
related pharmaceutical costs (P = 0.399). Mean
achievement of quality indicators across all eight
prescribing areas was 79.0% (standard deviation
4.4%). There were small positive correlations in
five prescribing areas: influenza vaccination, beta
blockers, angiotensin converting enzyme
inhibitors, lipid lowering, and antiplatelet
treatment (all P<0.001). Therewere small negative
correlations in two prescribing areas: hypertension
(P<0.001) and smoking cessation (P = 0.018).
Conclusion
Correlations between prescribing quality and
pharmaceutical costs weremuch smaller than
expected; possible explanations for this include a
substantial variation in rates of prescribing
outside evidence-based protocols, and use of
expensive pharmaceuticals instead of cheaper
effective alternatives. There remains
considerable scope for some practices tomake
pharmaceutical cost savings while improving
quality performance. The ratio of quality scores
to related pharmaceutical costs could be
developed into a performance indicator.
Keywords
cost effectiveness; economics, pharmaceutical;
primary health care; quality indicators; quality
of health care.
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Data collection
The study group obtained data for all 26
indicators, which included a prescribing
intervention in the QOF, for all 8409
practices in England for 2005–2006 (A
Wagner, personal communication, 2006).
These indicators were grouped into eight
distinct prescribing areas:
• angiotensin converting enzyme (ACE)
inhibitor and angiotensin receptor
blocker (ARB) treatment;
• antiplatelet treatment;
• beta blockers;
• diabetes (control of blood sugar);
• hypertension;
• influenza vaccination;
• lipid lowering; and
• smoking cessation.
Pharmaceutical spend for each of the 26
prescribing interventions was obtained for
every practice in England for 2005–2006
from the Prescription Pricing Division
(Prescription Pricing Authority, unpublished
data, 2007).
Other variables known to be associated
with variation in pharmaceutical costs and
quality performance at practice level were
identified from a previous study in English
primary care.8 These were: disease
prevalence; number of GPs; proportion of
female GPs and GP trainers; dispensing
status; rural or urban location; deprivation
status, as estimated by the low income
score index; consultation length; and
generic prescribing rates. These data were
obtained from the National Primary Care
Trusts Database (A Wagner, personal
communication, 2006).
Data analysis
Adataset containingQOFprescribing quality-
indicator performance, pharmaceutical costs,
and practice and population characteristics
for 2005–2006 was constructed for all 8409
practices in England. Practices for which
data were not available and those with a list
size of less than 1000 (n = 24) were
excluded.
Theunweightedmeanscore for all 26QOF
prescribing indicators was used to create an
overall combinedquality score (0–100%), and
a quality score was produced for each
prescribing area. To compute the related
prescribing costs, the pharmaceutical costs
related to each prescribing area were
divided by the number of patients on the
disease registers in that area, creating a
pharmaceutical cost per QOF patient for
each prescribing area. An overall combined
pharmaceutical cost per QOF patient was
determined by adding together the
pharmaceutical costs for all eight
prescribing areas, and dividing this number
by the total number of patients on the
disease registers in theQOF for thoseareas.
The relationships between the quality
scores and associated pharmaceutical
costs were analysed using both simple
bivariate correlation and multiple
regression analysis, along with other
possible explanatory variables in SPSS
(version 16). Pearson’s correlation
coefficient and linear regression were used,
as both quality performance and
pharmaceutical costs were normally
distributed.
Sensitivity analysis
Simply adding together or averaging out
individual quality scores has been criticised
as it assumes that all interventions are
equally effective and carry the same
weighting in combination.14 This problemwas
addressed in sensitivity analysis by weighting
eachQOFprescribing indicatorby itspotential
to save lives, usingdata fromaprevious study
on the health gain potential of the QOF.13 This
allowed the combination of the different
indicators into a single summary indicator,
usingweights based on health gain.
RESULTS
The mean quality score across all
prescribing areas was 79.0% (standard
deviation [SD] 4.4%; Table 1), and the mean
pharmaceutical spend per QOF patient
£149.79 (SD £35.32; Table 2). The statistical
dispersion of the prescribing costs was four
times greater compared with the quality-
indicator scores (coefficient of variation of
combined quality score = 0.06%, and of
How this fits in
Previous research has identified substantial
variation in both quality-indicator
performance and prescribing costs in
primary care practices, but the strength of
the relationship between quality-indicator
performance and associated prescribing
costs is not known. This cross-sectional
analysis of every GP practice in England
with available data found individually small
and collectively insignificant associations
between quality performance and
associated pharmaceutical costs in eight
prescribing areas. Some practices could
make considerable pharmaceutical cost
savings while, at the same time, improving
quality performance.
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Table 1. Prescribing quality-indicator scores in eight prescribing
areas
General Mean quality Standard Coefficient of
Prescribing area practices, n indicator score, % deviation variation, %
ACE/ARB 7618 82.05 8.62 0.11
Antiplatelet therapy 7975 89.75 5.62 0.06
Beta blockers 7997 50.94 8.16 0.16
Diabetes 8154 76.43 7.67 0.10
Hypertension 7996 74.83 7.82 0.10
Influenza vaccination 7982 79.26 6.83 0.09
Lipid lowering 7997 70.00 9.51 0.14
Smoking cessation 7817 92.08 5.78 0.06
Combined score 7491 79.01 4.41 0.06
ACE = angiotensin converting enzyme. ARB = angiotensin receptor blocker.
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Table2.Prescribing cost in eight prescribingareas
Pharmaceutical
General spendper Standard Coefficientof
Prescribingarea practices,n QOFpatient,£ deviation,£ variation,%
ACE/ARB 7978 855.35 587.89 0.69
Antiplatelet therapy 7833 79.07 31.38 0.40
Beta blockers 7985 52.86 28.04 0.53
Diabetes 7986 195.29 47.36 0.24
Hypertension 5417 87.23 17.99 0.21
Influenza vaccination 7982 29.94 21.46 0.72
Lipid lowering 7985 345.12 158.00 0.46
Smoking cessation 7981 21.56 13.31 0.62
Combined cost perQOFpatient 5473 149.79 35.32 0.24
ACE = angiotensin converting enzyme. ARB = angiotensin receptor blocker. QOF = Quality and Outcomes
Framework.
combined pharmaceutical costs = 0.24%).
Table 3 details the associations between
the achievement of prescribing quality
indicators and pharmaceutical costs. There
was no association between overall
prescribing quality-indicator achievement
and associated pharmaceutical costs
(Pearson’s r –0.012, P = 0.399, multiple
regression beta coefficient on cost 0.003, P
= 0.093); the sensitivity analysis gave similar
non-significant results with overall quality
score weighted by health gain as the
dependent variable (Pearson’s r –0.022, P =
0.110 and multiple regression beta
coefficient on cost –0.008, P = 0.788). There
were small statistically significant
associations in individual prescribing areas,
although these were not consistent.
Positive associations between
prescribing quality-indicator achievement
and associated pharmaceutical spend
existed in five areas: ACE/ARB treatment
(Pearson’s r 0.141, P<0.001); antiplatelet
treatment (Pearson’s r 0.058, P<0.001); beta
blockers (Pearson’s r 0.149, P<0.001);
influenza vaccination (Pearson’s r 0.167,
P<0.001); and lipid lowering (Pearson’s r
0.092, P<0.001). There were negative
associations in two areas: hypertension
(Pearson’s r –0.058, P<0.001) and smoking
cessation (Pearson’s r –0.027, P = 0.018).
These associations are small: for example
with beta blockers, the square of the
Pearson’s r of 0.149 = 0.022, suggesting that
variation in prescribing cost explains only
2.2%of theQOFscore variation. An increase
in pharmaceutical spend of £1 per patient
on beta blockers (just over 2% of the mean
spend of £52.86 on beta blockers per
patient) is associatedwith an increase in the
quality indicator of just 0.047 of one
percentage point.
There was a consistent positive
association between prescribing quality-
indicator achievement and higher rates of
generic prescribing. Higher prescribing
quality-indicator achievement was also
associated with being a dispensing practice
in all eight prescribing areas. Increasing
deprivation scores represented by the low
income score index were associated with
falling quality scores in five clinical areas
(available from the authors).
Scatter plots (available from the authors)
displayed some unusual patterns in three
clinical areas. In ACE/ARB treatment and
antiplatelet therapy, some practices
reported 100%performance. As it is unlikely
that all patients would be both eligible and
receive treatment, this finding may reflect
an error in the data at the practice level. In
smoking cessation, several practices
achieved high quality performance without
incurring significant prescribing costs. This
area is, however, unique for two reasons:
smoking cessation services were delivered
by some primary care trusts in the
community with no additional cost to the
practice, and achievement of this indicator
involves giving advice on smoking cessation
and does not necessitate prescribing
smoking cessation drugs. Advice-giving
could reach almost 100% of the practice
population that smokes.
DISCUSSION
Summary
There was no statistically significant
relationship between the combined
prescribing costs for each general practice
in England and their achievement of the
combined quality indicator. Within individual
prescribing areas there were some small
associations between cost and quality;
these were positive in five areas (ACE/ARB,
antiplatelet treatment, beta blockers,
influenza vaccination, and lipid lowering),
and negative in two areas (hypertension and
smoking cessation).
Strengths and limitations
The strength is that this study uses data on
performance and prescribing, and
combines them to perform a systematic
analysis of costs and quality. The data were
adjusted for patients who had been
excluded on the basis of not being suitable
for the intervention (by the process of
exception reporting by general practices).
There are a number of limitations. The
study only provides a partial indication of the
cost-effectiveness of prescribing because
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Table 3. Associations between achievement of prescribing quality
indicator and related pharmaceutical spend, in eight prescribing
areas and all areas combined
Correlation Correlation
Prescribing area (multiple regression)a (bivariate)
ACE/ARB R2 0.033 Pearson’s r 0.141
Beta 0.003 P-value <0.001
P-value <0.001 n 7600
Antiplatelet treatment R2 0.020 Pearson’s r 0.058
Beta 0.014 P-value <0.001
P-value <0.001 n 7811
Beta blockers R2 0.042 Pearson’s r 0.149
Beta 0.047 P-value <0.001
P-value <0.001 n 7962
Diabetes R2 0.098 Pearson’s r 0.000
Beta 0.005 P-value 0.998
P-value 0.007 n 7960
Hypertension R2 0.044 Pearson’s r –0.058
Beta –0.021 P-value <0.001
P-value <0.001 n 5415
Influenza vaccination R2 0.108 Pearson’s r 0.167
Beta 0.001 P-value <0.001
P-value <0.001 n 7946
Lipid lowering R2 0.076 Pearson’s r 0.092
Beta 0.009 P-value <0.001
P-value <0.001 n 7962
Smoking cessation R2 0.027 Pearson’s r –0.027
Beta –0.012 P-value 0.018
P-value 0.018 n 7790
Combined score, equal weights R2 0.080 Pearson’s r –0.012
Beta 0.003 P-value 0.399
P-value 0.093 n 5176
Sensitivity analysis, combined R2 0.061 Pearson’s r –0.022
score with health gain weights Beta –0.008 P-value 0.110
P-value 0.788 n 7497
aBeta = non standardised beta coefficient on cost; coefficients on other covariates are available from the
authors. ACE = angiotensin converting enzyme. ARB = angiotensin receptor blocker.
routinedatawerenot available on thehealth
outcomes of care or the non-
pharmaceutical costs related to
prescribing, such as GP and nurse time. In
addition, the PACT data used does not
indicate whether prescribing was
appropriate, as these data are aggregated
at the practice level and not linked to the
patient record.
It was not possible to determine how
much of the variation in pharmaceutical
costs was due to the choice of expensive
drugs over cheaper alternatives.
The study did not examine organisational
constraints and incentives on GPs’
prescribing behaviour and there may be
other unknown variables not included in the
analysis that could explain some of the
variation in practice.
Although the QOF clinical indicators are
only cost-effective in certain circumstances,
this study did not measure the amount of
prescribing outside of those. The
prescribing that fell within scope of the QOF
was measured in the current study, but
other studies have shown that such
prescribing is only cost-effective in certain
circumstances. As an example: clopidogrel
was not cost-effective when compared with
aspirin in patients with myocardial
infarction;15 aspirin may have no place in
primary prevention;16 guidance from the
National Institute for Health and Clinical
Excellence does not recommend beta
blockers for anxiety because of evidence for
lack of efficacy;17 the British National
Formulary does not recommend clonidine
for migraine because of its side-effect
profile;18 influenza vaccination is not cost-
effective in patients who are healthy;19 and
statins are only cost-effective in primary
prevention when used for high-risk
patients20 and those who are low risk may
get no benefit at all.21
Assuming that there is an appropriate
rate of prescribing of QOF drugs outside of
QOF indications by each practice, this
shouldnot alter the slopeof the cost–quality
relationship. These limitations do not alter
the conclusion that there is considerable
scope for practices tomake pharmaceutical
savings while improving performance.
Comparison with existing literature
These results update and extend to a
national sample the previously reported
lack of association between the quality and
costs of prescribing in one region of
England.8 They complement the previous
finding that the widely differing prescribing
rates in general practices in England were
not explained by healthcare need.7 This
study found that higher generic prescribing
was associated with higher-quality
performance, despite earlier findings that
generic prescribing was primarily aimed at
cost minimisation rather than quality
performance.22 The relationship between
increasing deprivation (using the low
income score index as the proxy) and
decreasing quality-indicator performance is
similar to findings from a study of general
practices in Scotland.23 The reported high
achievement of indicators (79%) is similar to
the achievement reported in a national
study of 8688 people in England using
different methods (74.6% achievement of
QOF conditions).24
Implications for research and practice
If GP prescribing were uniformly cost-
effective, a substantial positive association
between cost and quality would be
expected. For example, if prescribing statins
is limited to patients at high risk according
to QOF indicator definitions, using a cost-
effective statin such as simvastatin would
cost £46.41 per patient in 1 year. Other
things being equal, an increase in
prescribing costs of £1 per QOF patient
wouldbeassociatedwithan increaseof 2.15
percentage points in quality-indicator
performance. However, the beta coefficient
in the current study is 0.009, indicating that
an increase in prescribing cost of statins of
£1 per QOF patient is associated with an
increase of only 0.009 of a percentage point
in quality-indicator performance; that is,
278 times smaller than expected. As such,
the observed cost–quality associations in
five of the individual prescribing areas are
much smaller than would be expected if
prescribing were uniformly cost-effective.
This is, therefore, fairly clear evidence
that prescribing is not uniformly cost-
effective, and that some GP practices are
able to achieve higher prescribing quality
scores than others, while keeping their
prescribing costs substantially lower. This
study’s data do not allow us to pinpoint the
reasons for the lack of any strong positive
association between prescribing quality-
indicator achievement and associated
pharmaceutical costs, but there are two
broad possibilities. GPs may vary
considerably in their use of more expensive
drugs compared with less expensive drugs;
the Audit Commission has estimated that
the use of more expensive drugs over
cheaper alternatives cost an additional
£200 million in England in 2006.25 In
addition, there may also be a wide variation
in their prescribing of QOF-indicated drugs
to patients outside QOF areas of care.
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Prescribing is not cost-effective if a practice
has a low rate of prescribing recommended
drugs to high-benefit patients included in
QOF domains, but has high rates of
prescribing these drugs to patients outside
QOF domains where such drugs are not
supported by a strong evidence base.
There could be substantial savings in
drug expenditure if GPs use QOF-indicated
drugs appropriately, and use cheaper drugs
when available. At present, the QOF
incentivises high performance in indicators
but does not explicitly incentivise cost-
effective prescribing.11 As no relationship
between the cost and quality of prescribing
was found, theoretically, all practices
should be able to prescribe at low cost with
high quality. Practices performing at low
quality and high cost could be targeted first
for change as these comprise the areas
where maximum quality and cost gains
could be realised.
This study’s approach to assessingquality
performance as a ratio of the quality scores
to related pharmaceutical costs could be
developed into a performance indicator that
includes aspects of both quality
performance and prescribing costs. If
further research supports the findings of
this study, incentives could be used through
GP consortia to reduce pharmaceutical
costs while maintaining and improving
quality. Unanswered questions and areas
for future research include examining the
patient record to establish howmuch of the
variation in prescribing costs is due to
inappropriate prescribing and how much is
due to the use ofmore expensive drugs over
cheaper alternatives.
The association between prescribing
quality indicators and pharmaceutical costs
may have increased since 2005–2006, but
the continuedoperation of theQOFmeansa
dramatic change is unlikely. This is because
the QOF focuses on reducing inappropriate
variation in high-benefit prescribing, which
drives the quality side of the equation but
does not address the inappropriate variation
in low-benefit/high-cost prescribing that
drives the cost element. The slowdown in
NHS spending from 2010–2011 may put
pressure on practices to reduce
pharmaceutical costs, so we may see a
stronger association emerge in the next few
years.
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Appendix 1. Full descriptions of Quality and Outcomes Framework
indicators
Indicator Full description of clinical indicator
Asthma 5 The percentage of patients with asthma who smoke, and whose notes contain a record
that smoking cessation advice or referral to a specialist service, if available, has been
offered within the last 15 months
Asthma 7 The percentage of patients aged 16 or over with asthma who have had influenza
immunisation in the preceding 1 September to 31 March
BP 3 The percentage of patients with hypertension who smoke, whose notes contain a record
that smoking cessation advice or referral to a specialist service, if available, has been
offered at least once
BP 5 The percentage of patients with hypertension in whom the last blood pressure
(measured in the last 9 months) is 150/90 or less
CHD 4 The percentage of patients with coronary heart disease who smoke, whose notes
contain a record that smoking cessation advice or referral to a specialist service, where
available, has been offered within the last 15 months
CHD 6 The percentage of patients with coronary heart disease in whom the last blood pressure
reading (measured in the last 15 months) is 150/90 or less
CHD 8 The percentage of patients with coronary heart disease whose last measured total
cholesterol (measured in last 15 months) is 5mmol/l or less
CHD 9 The percentage of patients with coronary heart disease with a record in the last 15 months
that aspirin, an alternative anti-platelet therapy, or an anti-coagulant is being taken
(unless a contraindication or side-effects are recorded)
CHD 10 The percentage of patients with coronary heart disease who are currently treated with a
beta blocker (unless a contraindication or side-effects are recorded)
CHD 11 The percentage of patients with a history of myocardial infarction (diagnosed after 1 April
2003) who are currently treated with an ACE inhibitor
CHD 12 The percentage of patients with coronary heart disease who have a record of influenza
immunisation in the preceding 1 September to 31 March
COPD 5 The percentage of patients with COPD who smoke, whose notes contain a record that
smoking cessation advice or referral to a specialist service, if available, has been offered
in the past 15 months
COPD 8 The percentage of patients with COPD who have had influenza immunisation in the
preceding 1 September to 31 March
DM 4 The percentage of patients with diabetes who smoke and whose notes contain a record
that smoking cessation advice or referral to a specialist service, where available, has
been offered in the last 15 months
DM 6 The percentage of patients with diabetes in whom the last HbA1C is 7.4 or less (or
equivalent test/reference range depending on local laboratory) in last 15 months
DM 7 The percentage of patients with diabetes in whom the last HbA1C is 10 or less (or
equivalent test/reference range depending on local laboratory) in last 15 months
DM 12 The percentage of patients with diabetes in whom the last blood pressure is 145/85 or less
DM 15 The percentage of patients with diabetes with proteinuria or micro-albuminuria who are
treated with ACE inhibitors (or A2 antagonists)
DM17 The percentage of patients with diabetes whose last measured total cholesterol within the
previous 15 months is 5 or less
DM 18 The percentage of patients with diabetes who have had influenza immunisation in the
preceding 1 September to 31 March
LVD 3 The percentage of patients with a diagnosis of CHD and left ventricular dysfunction who
are currently treated with ACE inhibitors (or A2 antagonists)
Stroke4 The percentage of patients with a history of TIA or stroke who smoke and whose notes
contain a record that smoking cessation advice or referral to a specialist service, if
available, has been offered in the last 15 months
Stroke 6 The percentage of patients with a history of TIA or stroke in whom the last blood pressure
reading (measured in last 15 months) is 150/90 or less
Stroke 8 The percentage of patients with TIA or stroke whose last measured total cholesterol
(measured in last 15 months) is 5mmol/l or less
Stroke 9 The percentage of patients with a stroke shown to be non haemorrhagic, or a history of
TIA, who have a record that aspirin, an alternative anti-platelet therapy, or an
anticoagulant is being taken (unless a contraindication or side-effects are recorded)
Stroke 10 The percentage of patients with TIA or stroke who have had influenza immunisation in the
preceding 1 September to 31 March
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Appendix 2. Allocation of Quality andOutcomes Framework (QOF) indicators to prescribing areas and
relatedBritishNational Formulary (BNF) chapters, potential lives saved for eachQOF indicator, and
therapeutic indications for QOFdrugs outside QOF
Other therapeutic indications
Drugs Max lives savedper fordrugsoutsideQOF
Prescribingarea QOF indicatora11 (BNFchapter)18 100 000population13 indicatordefinitions (BNF indications)18
ACE/ARB CHD11 ACE/ARB (2.5.5) 1.5 Heart failure
LVD3 11.6
DM15 3.4
Antiplatelet treatment CHD9 Aspirin 75mg (2.9) 24.8 Prophylaxis of CHD
Stroke9 Clopidogrel (2.9) 15.8 Peripheral vascular disease
Dipyridamole (2.9) None
Beta blockers CHD10 Beta blocker (2.4) 45.9 Arrhythmia
Portal hypertension
Thyrotoxicosis
Heart failure
Anxiety
Phaechromocytoma
Diabetes DM6 Insulin/hypodermic (6.1.1) 26.5 None
equipment
DM7 Oral antidiabetic agent (6.1.2) 7.4
Hypertension CHD6 Thiazide (2.2.1) 11.3 Oedema
BP5 Beta blocker (2.4) 48.2 (listed above)
DM12 Vasodilator (2.5.1) 13.5 Heart failure (hydralazine only)
Stroke6 Centrally acting (2.5.2) No data Migraine (clonodine only)
Alpha blocker (2.5.4) Benign prostatic hypertrophy
ACE (2.5.5.1) (listed above)
ARB (2.5.5.2) (listed above)
Ca channel (2.6.2) None
Influenza vaccination CHD12 Influenza vaccines (14.4) 61.6 Immunosupression
Stroke10 28.1 Front-line healthcareworkers
DM18 63.7
COPD8 25
Asthma7 No data
Lipid lowering treatment CHD8 Lipid regulating drugs (2.12) 15.8 Primary hypercholesterolaemia
Stroke8 No data
DM17 No data
Smoking cessation treatment CHD4 NRT 2.4 None
Stroke4 Bupropion (both part of 4.10) 1.1
BP3 5.4
DM4 2.4
COPD5 2.6
Asthma5 8.8
ACE = angiotensin converting enzyme. ARB = angiotensin receptor blocker.
